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ABSTRACT 
 
Time has come for a survey of our knowledge on the physical interaction between the 
growth-promoting insulin molecule and retinoblastoma tumor suppressor protein 
(RB). Theoretical and experimental observations over the past 15 years reviewed here 
indicate that the insulin-RB dimer may represent an essential molecular crossroads 
involved in major physiological and pathological conditions. Within this system, the 
putative tumor suppressor insulin-degrading enzyme (IDE) should be an important 
modulator. Perhaps most remarkably, the abstraction of this encounter between 
insulin and RB, two growth-regulatory giants acting either in concert or against each 
other depending on the respective cellular requirements, reveals that Nature may 
compute in controlling cell fate and we could follow in its footsteps towards 
developing more efficient therapeutics as well as novel technical devices. 
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Insulin meets RB: synopsis of a discovery 
 
Biological information is encoded in individual genes and proteins, yet life emerges 
from multiple interactions among various such molecules. A prominent paradigm for 
these events is the docking of ligands floating in the extracellular space to receptors 
located on the surface of cells. Within this category, one example of central 
importance to cell metabolism is the complex formation between insulin and the 
insulin receptor. 
Investigations carried out over the past 15 years, however, revealed that, 
besides binding and thereby recruiting the (cell membrane) insulin receptor as a 
molecular switchboard for signal transduction, insulin likely targets a second crucial 
molecule in order to decisively influence cell fate: the (nuclear) retinoblastoma tumor 
suppressor protein (RB). Accordingly, it was initially shown that insulin harbors the 
LXCXE RB-binding motif (1) and subsequently demonstrated that insulin indeed 
physically interacts with RB, specifically the latter´s predicted insulin binding site 
synthesized as a peptide (2), and also the full-length RB protein in the context of 
living human tumor cells (3-5). Moreover and interestingly, the predominantly 
nuclear contact formation between insulin and RB was shown to correlate with an 
increase in cell proliferation (3), suggesting that, similar to RB-binding viral 
oncoproteins, the attachment of insulin to RB inhibits RB´s antiproliferative 
function.  
The potentially paramount importance of the insulin-RB encounter is further 
underscored by a third player likely to impact on this growth-regulatory system: 
insulin-degrading enzyme (IDE). In 1994, it was initially hypothesized that IDE may 
exert tumor-suppressive activity by preventing that insulin moves into the nucleus 
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and subsequently neutralizes RB, the net effect being a maintenance of natural cancer 
prophylaxis by functional RB (6). 
A decade later, a striking homology between IDE and RB was identified which 
indicated an unexpected capacity of RB to act as an insulin-degrading protease by 
virtue of a zinc-binding catalytic site similar to that present in IDE and located in the 
carboxyterminal moiety of RB (7). Conversely, this structural kinship conferred 
further plausibility to the above 1994 hypothesis on IDE being a putative tumor 
suppressor. 
Intriguingly, a first experimental study on IDE in human cancer tissues 
appears to confirm the validity of this concept as IDE was shown to be overexpressed 
in breast cancer vs. normal breast, yet underexpressed in lymph node metastases vs. 
primary tumors (8), consistent with the notion of a gradual loss of IDE tumor-
suppressive activity with progressive oncogenesis and similar to the biphasic 
expression patterns of Bax (9) and HtrA1 (10). 
It is noteworthy that this first published demonstration of IDE in human 
malignancies had been preceded by extensive investigations gradually eliminating 
potential staining pitfalls (11) and thus establishing the reliability of the finally 
employed immunohistochemical method (8). 
While the above theoretical and experimental studies on the potentially 
antineoplastic role of IDE opened the door a crack into this direction, a most recent 
insight pushed it wide open: it was the recognition that insulin antagonism may be a 
more widespread phenomenon as a natural means to protect (nuclear) RB and shared 
by proteins mechanistically as diverse as IDE, phosphatase and tensin homologue 
(PTEN) and insulin-like growth factor binding protein 7 (IGFBP-7), hence providing 
a heretofore unknown second principle besides cyclin-dependent kinase inhibition 
through p16, p21 and/or p27 for maintaining the antiproliferative activity of RB (12). 
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As if such a variety of insulin-antagonistic RB protectors had not sufficed, 
Nature seems to have endowed also RB itself with the propensity for self-defense. 
Beyond the above mentioned potential for RB to degrade insulin (7), RB may leave 
the cell by virtue of a putative N-terminal signal peptide (13) and interfere with the 
docking of insulin to its cell membrane receptor in the extracellular compartment 
(14), thereby preventing the initiation of phosphorylation cascades which would 
otherwise inactivate nuclear RB. 
It is, however, also conceivable that this proposed RB interference with insulin 
signal transduction may not require RB secretion since intracellular RB could also 
avert intracrine insulin receptor activation by internalized or de novo synthesized 
insulin, thus abrogating a growth-stimulatory loop similar to short circuits previously 
described for isoforms of PDGF (15) and FGF (16) as well as for IL-3 (17). 
 
 
The insulin-RB heterodimer and its modulators in specific conditions 
 
Since there is no major protein-protein interaction relevant only in pathology, one 
should first consider the potential role of the insulin-RB complex in physiology. As 
such, it could be surmised that an increased quantity of insulin-RB heterodimers 
contributes not only to the rapid phases of embryonic and fetal development, but also 
to tissue regeneration following injury. The latter may be particularly applicable 
within the liver which is known to be an organ with a high capacity for self-renewal 
and under circumstances where insulin is employed therapeutically to accelerate 
wound closure and thereby restore tissue integrity (18). Consequently, a potentially 
oncogenic molecule such as insulin would be capable of cooperating with RB- by 
recruiting its cell survival-promoting function (19) while interfering with its 
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antiproliferative actions- towards a physiological goal, thus resembling the Ras-RB 
cooperation during cell differentiation (20). 
 By contrast, under other circumstances, a predominance of this dimer may be 
deleterious. Accordingly, the natural tropism of insulin towards RB, if unbalanced, 
could contribute to the insulin resistance syndrome including type 2 diabetes mellitus 
and obesity as well as ultimately accelerate the aging process (21). Moreover, 
excessive insulin-RB encounters are likely to represent a major signal for 
carcinogenesis (1,3,22). Briefly, overflowing insulin predictably keeps RB from 
performing its anti-cancer and anti-aging tasks (14, 21, 23). 
Beyond aging and cancer, the insulin-RB complex may be involved in the 
pathogenesis of various neurodegenerative conditions such as Alzheimer´s disease 
(AD). Foregoing this possible involvement would be a state of hyperinsulinemia- an 
aberrancy known to be associated with AD- causing a reactive increase in the number 
of insulin receptors and, upon their activation, an upregulation of IDE (24) that, with 
further disease progression, largely fails to fulfill its task to degrade insulin (and 
amyloid). As a result, internalized insulin could undergo unhindered translocation to 
the nucleus with subsequent binding of a significant amount of RB molecules. Given 
the post-mitotic nature of neurons, a predominance of insulin-RB nuclear contacts 
should then lead to cell death, not proliferation.  
Most recently, it became apparent that the insulin-RB complex may also 
enhance pain signalling (25).  The basis for this assumption is the fact that an 
analgesic spider venom peptide termed psalmotoxin 1 (26) was found to contain the 
PKT amino acid sequence in duplicate (27), i.e. a tripeptide  identical to the signature 
postulated to enable RB to interfere with insulin´s binding to its receptor (14), 
suggesting that RB could block not only insulin´s pro-aging effects (14), but also its 
likely potentiation of pain signal transmission through PI3kinase (28).  
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Similar to the insulin-RB aging model in which insulin retains and inactivates 
RB in the nucleus such that the latter can no longer interfere with insulin-insulin 
receptor association, thus promoting aging (21), excessive insulin-RB dimerization 
would also abrogate RB´s contribution to analgesia and result in hyperalgesia. 
Therefore, compounds known to antagonize the physical interaction between 
insulin and RB such as MCR peptides should be able to block not only cancer growth 
(3,5,29-35), but equally counteract organismal senescence (21), attenuate 
neurodegenerative disorders (36) and reduce pain sensation (37). 
 
 
General implications and outlook 
 
The question is then why Nature selected for the encounter between insulin and RB 
in various major conditions, physiological or pathological, or, more generally 
speaking, for nucleocrine communication, the insulin-RB dimer representing its 
paradigm (38), yet the EGF precursor-p130 complex being also an important 
example (39). Interestingly, a novel view may provide both the likely answer and 
open up a largely uncharted territory for future investigations. Accordingly, the 
insulin-RB complex may be best understood in terms of a novel theory for 
(biological) information transfer governed by the following equation: 
 
Fi = m ai 
 
where Fi is the cybernetic force affecting a given (biological) system (e.g. a cell), m is 
the mass of a given cue (e.g. a biologically active molecule) and ai is its cybernetic 
acceleration.  
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 The cybernetic acceleration ai itself may be defined as ai = 1/n where n is the 
number of intermediary objects required for a cue to change the state of a system 
(e.g. for translating the message of a biological molecule into a modification of gene 
expression). Specificity of such accelerated information transfer would then reside in 
the structure of the cue, e.g. in the amino acid sequence of a signalling protein or 
peptide. 
In keeping with this definition, for those insulin molecules present in insulin-
RB dimers, n is to be assigned a value of 1 since only RB, i.e. one molecule, mediates 
between insulin and DNA which in turn would yield the maximum ai value of 1 (more 
precisely, ai = 1/1 =1) and, ultimately, in conjunction with insulin´s m value, the 
maximally achievable cybernetic force Fi. In other words, whenever there is no 
intermediary or yet only one intermediary to the gene-regulatory action of a 
molecule, this embodies maximal cybernetic simplicity and thus efficiency. 
By contrast, if an extracellular ligand docking to a cell membrane receptor 
needs 5 intermediary molecules for its information to be relayed to the genes in the 
cell nucleus such that ultimately gene expression is switched on or off, this would 
yield a value of 1/5 or 0.2 for ai of the given ligand. 
In this context, a special case is, for instance, insulin since this hormone and 
growth factor may both activate a cell membrane receptor and hence entrain a post-
receptor signal transduction cascade involving many molecules, yet also translocate 
to the nucleus to bind RB. In this case, one would have to distinguish the two 
functional isoforms and assign to them distinct Fi values accordingly. 
 In the light of these new considerations, the insulin-RB complex translates 
into maximal velocity for the transmission of insulin-enciphered biological 
information, and, as such, is a first candidate for driving cell proliferation within the 
cybernetics of cancer (40). Notably, my present perception is consistent with the 
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concept of "regulated protein translocation" as a source of specificity and acceleration 
in biological signal transduction (41). 
 As knowledge penetrates into increasingly microscopic dimensions, I also 
propose to perceive the key contact formation occurring between insulin and RB as a 
(molecular) synapse, hence paralleling the relatively more macroscopic synapses 
between neurons or yet those created within the immune system by dendritic cells 
and T lymphocytes. 
 Due to its implications for biology and beyond, further thinking into the 
insulin-RB complex and congeners could push the cybernetic frontier far ahead. 
Ultimately, a new discipline may arise, akin to rocket science and thus contrasting the 
"black box" of conventional transcriptional activators (42). 
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